Phase 2 N=40 Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Neurogenic Orthostatic Hypotension
Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure — 19; 3 mm Hg
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 3 N=263 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
Phase 3 N=195 Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 — -1.69; -1.45 score on a scale — p=0.574
Phase 3 N=103 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Neurogenic Orthostatic Hypotension · Non-Diabetic Autonomic Neuropathy · Multiple System Atrophy
Primary: Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) — 0.57; 0.90 units on a scale — p=0.438
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Phase 3 N=350 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
Phase 2 N=33 Safety Study of Pyridostigmine in Heart Failure
Heart Failure
Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 3 N=28 Peripheral Dopamine in Postural Tachycardia Syndrome
Postural Tachycardia Syndrome · Orthostatic Intolerance
Primary: 24 Hour Urinary Sodium Excretion During Treatment Normalized to Creatinine — 140; 132; 137; 154 Milliequivalents per gram (mEq/g)
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
Phase 2 N=3 NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
Menkes Disease · Occipital Horn Syndrome
Primary: Treatment Related Adverse Events as Assessed by CTCAE v4.0 — 10; 6 adverse events
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
Phase 2 N=22 Carbidopa for the Treatment of Excessive Blood Pressure Variability
Dysautonomia, Familial · Baroreflex Failure Syndrome
Primary: Number of Participants Who Reported Adverse Events Related to Study Drug — 0; 0; 0 Participants
Phase 2 N=22 A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
Phase 3 N=6 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
N/A N=20 Nebivolol in the Supine Hypertension of Autonomic Failure
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure During the Night — 154; 162; 157; 158 mm Hg — p=0.036
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Phase 3 N=12 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia
Familial Dysautonomia
Primary: Composite Daily Score — 6.9; 9.7 units on a scale
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
Phase 3 N=51 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
Orthostatic Hypotension · Parkinson's Disease
Primary: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -2.2; -2.1 units on a scale — p=0.978
N/A N=87 Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson Disease · Parkinsonian Disorders
Primary: Demonstrate the Presence of Alpha-Synuclein Inclusions in the Skin of Parkinson's Disease and Compare With an Atypical Parkinsonism Group and With a Healthy Control…
N/A N=112 Nitric Oxide and the Autonomic Nervous System
Hypertension · Pure Autonomic Failure
Primary: Change in Systolic Blood Pressure — 43; 21 mm Hg
N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
N/A N=30 The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84